Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.

Urology - 1 Feb 2024

Weiss Kristin, Abimbola Obafunbi, Miller Kelsey, Kim William Y, Rose Tracy L, Bjurlin Marc A, Gessner Kathryn H

Abstract excerpt

In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Cisplatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, erbB-2

Share to Mutation

Share to Neoplasm, Residual

Share to Platinum

Share to Receptor, ErbB-2

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38052324
DOI: 10.1016/j.urology.2023.11.019
PMCID: PMC11364485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.PMID 38052324Read ↗

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.Semantic proximity Read ↗

HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.Semantic proximity Read ↗

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.Semantic proximity Read ↗

Durable Response to Trastuzumab Deruxtecan in a Patient with Urothelial Cancer and ERBB2 Mutation: A Case ReportSemantic proximity Read ↗

The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.Semantic proximity Read ↗

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.Semantic proximity Read ↗

HER2 as a target in invasive urothelial carcinoma.Semantic proximity Read ↗

Chemotherapy for metastatic bladder cancer.Semantic proximity Read ↗

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese PopulationSemantic proximity Read ↗

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancerSemantic proximity Read ↗

Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.Semantic proximity Read ↗

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.